24 Therefore, considering that GLP-1R is widely distributed in the body, that COPD and diabetes interact with each other and share common pathogenic mechanisms, and that GLP-1 and its receptor agonists have been widely used in diabetic patients and have demonstrated hypoglycemic, pro-inflammatory and anti-inflammatory factors, oxidative stress, neurogenesis and vascular protection, 33 then GLP-1 and its receptor agonists also have a role to play in COPD patients
Klebanoff answered questions about his findings below
Reduction of lipid and protein damage in patients with disorders of propionate metabolism under treatment: a possible protective role of L-carnitine supplementation
A small banana, a handful of almonds, or a protein bar with under 200 calories gives enough energy without sitting heavy in the stomach
Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes
GLP-1 medications are not a permanent solution on their own - research on weight regain after discontinuation is ongoing, and many patients experience some weight regain after stopping therapy
